Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables Refunds
Ratios

Universe Pharmaceuticals (UPC) Accumulated Depreciation & Amortization (2020 - 2025)

Universe Pharmaceuticals' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $6.9 billion for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 3.59% to $6.9 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $6.9 billion, a 3.59% increase, with the full-year FY2025 number at $6.9 billion, up 3.59% from a year prior.
  • Accumulated Depreciation & Amortization hit $6.9 billion in Q3 2025 for Universe Pharmaceuticals, up from $6.7 billion in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for UPC hit a ceiling of $6.9 billion in Q3 2025 and a floor of $5.7 million in Q3 2022.
  • Historically, Accumulated Depreciation & Amortization has averaged $2.7 billion across 5 years, with a median of $6.1 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: dropped 1.21% in 2022 and later skyrocketed 110052.67% in 2024.
  • Tracing UPC's Accumulated Depreciation & Amortization over 5 years: stood at $5.8 million in 2021, then dropped by 1.21% to $5.7 million in 2022, then grew by 5.96% to $6.1 million in 2023, then skyrocketed by 110052.67% to $6.7 billion in 2024, then rose by 3.59% to $6.9 billion in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for UPC at $6.9 billion in Q3 2025, $6.7 billion in Q3 2024, and $6.1 million in Q3 2023.